Stoke reports Q1 net loss $50M; new 4-year OLE data supports zorevunersen disease-modifying potential

Stoke Therapeutics, Inc.

2026-Q1 EPS reported -$0.79 revenue$6,229,000

Net loss $50.0M ($0.79/share) vs prior-year net income $112.9M; revenue $6.2M down from $158.6M due to 2025 Biogen license revenue.
Cash $411M funded into 2028; includes $80.7M from ATM sales of 2.6M shares in Q1.
New 4-year OLE data: durable seizure reductions, statistically significant cognition/behavior gains at 1-4 years; generally well tolerated.
Phase 3 EMPEROR enrollment (~150 pts) expected to complete June 2026, data readout mid-2027; NDA submission planned Q1 2027.
First patient dosed in Phase 1 OSPREY (STK-002 for ADOA); SYNGAP1 candidate selection targeted in 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

Stoke Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

the Company today reported financial results for the first quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-212020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.